Navigation Links
InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMD's TCT Satellite Symposium in Washington DC., Today.
Date:9/24/2010

InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients.... -- WASHINGTON, September 24, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Trade Show News, Clinical Trials & Medical Discoveries Click to view news release full screen  

InspireMD Presents 2 Years Clinical Outcome of MGuard Multicenter Experience in STEMI Patients. The New Superb Clinical Results Were celebrated at InspireMD's TCT Satellite Symposium in Washington DC., Today.

 

WASHINGTON, September 24, 2010 /PRNewswire/ -- InspireMD sponsored a Satellite Symposium today at the TCT conference in Washington convention center, the symposium was chaired by Drs. Alexandra J. Lansky,and Roxana Mehran. The session titled "MGuard Embolic Protection Stent: Novel Primary PCI Solutions and Challenging Cases" manifested unprecedented clinical findings of long term MGuard Multicenter Experience in STEMI (heart attack) patients, presented by Prof. Federico Piscione, from Federico-II University in Naples, Italy. Prof. Piscione presented 2 years clinical follow up of 100 patients. In an analysis of non cardiogenic shock patients (89 patients), the MACE (cardiac death, MI, TVR) rate was 7.9% (vs. 13.3% in the total group). In addition, post procedural Blush grade 3 and complete ST segment resolution were both at 90%.

"The results we obtained with the MGuard stent" commented Prof. Piscione," show that MGuard is a safe and feasible option, both at short and long-term follow-up, for STEMI patients undergoing PCI with huge thrombus burden."

Mr. Ofir Paz, InspireMD's CEO, said "We are very excited with the new clinical results of MGuard. To date, 345 STEMI patients have been enrolled in selected clinical trials to test MGuard performance in this high risk population. The outcome surpasses today's best practice, in terms of acute results as well as long term clinical follow-up. When we performed a Meta analysis of all our STEMI trials the results reveal that with MGuard it may be possible to reduce MACE by up to an astonishing 50%."

About MGuard(TM) Coronary

MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection specifically designed for Acute MI patients. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The MGuard(TM) coronary stent provides permanent embolic protection, without affecting deliverability. MGuard(TM) is CE Mark approved. The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.

About InspireMD

InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis. In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.

Contact details: http://www.inspire-md.com Jonina Ohayon Marketing Director Tel +972-52-5791120 jonina@inspire-md.com
'/>"/>

SOURCE Inspire MD
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
2. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
3. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
4. InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San Francisco
5. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
6. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
7. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
8. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
9. GeoVax Presents Data at AIDS Vaccine 2008 Conference
10. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
11. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017  MIODx announced today that it has ... technologies from the University of California, San Francisco ... monitor a patient for response to immune checkpoint ... second license extends the technology with a method ... have an immune-related adverse event (IRAE) from their ...
(Date:2/23/2017)... 23, 2017  Seattle,s upscale Capitol Hill neighborhood, with its swanky ... for a head lice treatment salon to set up shop. ... restaurant and a French bistro on E Madison Ave, and ... just any old lice clinic, we pride ourselves on being ... release some of the stigma associated with lice. Everyone can ...
(Date:2/23/2017)... Antonio, TX (PRWEB) , ... February 23, 2017 ... ... Drug Administration (FDA) de novo clearance to begin marketing the SPEAC® System, the ... indicated for adults at home or in healthcare facilities during periods of rest. ...
(Date:2/23/2017)... ... 23, 2017 , ... David Nolte, PhD accepted Purdue University’s ... Purdue Research Park of West Lafayette, Indiana. , The top commercialization award ... and success with, commercializing discoveries from Purdue research. “This award is truly an ...
Breaking Biology Technology:
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:2/2/2017)... , Feb. 1, 2017  Central to ... and meaningful advances worldwide, The Japan Prize Foundation ... Prize, who have pushed the envelope in their ... and Communication. Three scientists are being recognized with ... achievements that not only contribute to the advancement ...
(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):